We did not assess the potential therapeutic roles of SRGN, PLEK, and FCGR3B in UC and RA; therefore, further clinical research is needed to investigate whether they could be used as predictive factors for infliximab efficacy in patients with UC and RA. The gene discussed is SRGN; the disease is rheumatoid arthritis.